News

VOLGA Trial Shows Survival Benefit With Durvalumab and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer

Clinical Trails /

High-level results from the phase 3 VOLGA trial show that combining durvalumab (Imfinzi) with enfortumab vedotin (Padcev) before surgery significantly improves survival for patients with muscle-invasive bladder cancer who cannot receive or choose not to receive cisplatin chemotherapy. The treatment improved both event-free survival and overall survival compared with surgery alone. Another treatment group using […]

VOLGA Trial Shows Survival Benefit With Durvalumab and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer Read More »

Phase 3 ENVISION Trial Shows Long-Term Bladder Cancer Control With Zusduri

Treatment /

New 3-year results from the phase 3 ENVISION trial show that Zusduri (mitomycin for intravesical solution) can provide long-lasting disease control for patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer. The study found that nearly two-thirds of patients who achieved a complete response after treatment remained cancer-free three years later. Patients received only a single

Phase 3 ENVISION Trial Shows Long-Term Bladder Cancer Control With Zusduri Read More »

10-Year Study Shows Long-Term Benefits of Ibrutinib in Chronic Lymphocytic Leukemia

Treatment /

A 10-year phase 2 study published in the journal Blood found that ibrutinib alone can provide long-lasting benefits for patients with chronic lymphocytic leukemia (CLL), including those with high-risk disease features. The study included 84 patients who were either newly diagnosed or had relapsed disease, many of whom had TP53 abnormalities or unmutated IGHV, both

10-Year Study Shows Long-Term Benefits of Ibrutinib in Chronic Lymphocytic Leukemia Read More »

CRISPR-Edited Stem Cells May Protect AML Patients From Treatment Toxicity

Research Advances /

A new study shows that CRISPR gene editing may help protect patients with Acute Myeloid Leukemia from the harmful side effects of intensive cancer treatment. In the VBP101 trial, researchers used CRISPR-Cas9 to remove the CD33 protein from donor stem cells before transplant. This created a new blood and immune system that could resist damage

CRISPR-Edited Stem Cells May Protect AML Patients From Treatment Toxicity Read More »

FDA Approves Sonrotoclax for Previously Treated Mantle Cell Lymphoma

Drug Approvals /

The U.S. Food and Drug Administration has granted accelerated approval to Sonrotoclax for adults with relapsed or refractory Mantle Cell Lymphoma who have already received at least two previous treatments, including a BTK inhibitor. The approval was based on results from the BGB-11417-201 trial involving 103 patients whose disease had returned after standard therapies. The

FDA Approves Sonrotoclax for Previously Treated Mantle Cell Lymphoma Read More »

New Therapy Targets “Zombie Cells” to Slow Cancer Growth and Aging

Research Advances /

Researchers have developed a new way to eliminate harmful “zombie cells” linked to cancer and aging. These senescent cells stop dividing but remain active, releasing substances that can damage tissue and help tumors spread. Scientists discovered that the cells survive by overproducing GPX4, a protein that protects them from Ferroptosis, a form of cell death

New Therapy Targets “Zombie Cells” to Slow Cancer Growth and Aging Read More »

Belamaf Quadruplet Therapy Shows Strong Responses in Relapsed Multiple Myeloma Trial

Clinical Trails /

A Phase 1/2 study found that combining Belantamab mafodotin with the KRd regimen (carfilzomib, lenalidomide, and dexamethasone) produced strong and durable responses in patients with relapsed or refractory multiple myeloma. Researchers tested a new dosing schedule for belamaf, giving the drug every eight weeks instead of every three weeks to reduce eye-related side effects while

Belamaf Quadruplet Therapy Shows Strong Responses in Relapsed Multiple Myeloma Trial Read More »

Study Links T-Cell Fitness to Glofitamab Success in Large B-Cell Lymphoma

Research Advances /

A study published in Blood found that the success of the T-cell engager glofitamab in relapsed or refractory large B-cell lymphoma (LBCL) depends heavily on the health and strength of a patient’s T cells. Researchers analyzed patients from the Phase 1/2 NP30179 trial and discovered that patients who responded well to treatment maintained higher levels of

Study Links T-Cell Fitness to Glofitamab Success in Large B-Cell Lymphoma Read More »

INBRX-106 Plus Keytruda Doubles Response Rate in Advanced Head and Neck Cancer Trial

Clinical Trails /

Interim results from the Phase 2 HexAgon study showed that adding the OX40 agonist INBRX-106 to Keytruda improved outcomes for patients with advanced head and neck squamous cell carcinoma (HNSCC). The combination treatment achieved a confirmed overall response rate of 44%, compared with 21.4% for Keytruda alone. Three patients receiving the combination therapy had a

INBRX-106 Plus Keytruda Doubles Response Rate in Advanced Head and Neck Cancer Trial Read More »

New PSMA Radioligand Therapy Shows Strong Results in Advanced Prostate Cancer Trial

Clinical Trails /

A Phase 1 study found that the new radioligand therapy [177Lu]Lu-D-Dan-Phe-PSMA is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC). The treatment was designed to stay in the body and tumors longer than current therapies such as Pluvicto, allowing it to deliver more radiation directly to cancer cells. In the highest dose

New PSMA Radioligand Therapy Shows Strong Results in Advanced Prostate Cancer Trial Read More »